OXURION overview

Leuven, BELGIUM – April 11, 2025 – 08:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2024. The annual report for the year ending December 31, 2024 is available in the “Investors” section of the Company's website and can also be downloaded as a PDF. On this day as well, the Company has convened its Annual Shareholders' Meeting. The relevant documents pertaining to this...

Leuven, BELGIUM – April 4, 2025 – 02:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today made the following announcement regarding the financial calendar: Due to administrative reasons, the annual accounts of the Company have not been finalized yet. Hence, the Company has decided to postpone its Annual Shareholders Meeting to Tuesday May 13, 2025. About Oxurion Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation...

Leuven, BELGIUM – April 2, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on April 1, 2025, from Atlas Special Opportunities II, LLC indicating that as of March 31, 2025, it held 925,088 shares of the then outstanding 4,634,663 shares, and therefore crossed...

Leuven, BELGIUM – March 27, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received transparency notifications as follows: Oxurion received a transparency notification on March 27, 2025, from Atlas Special Opportunities II, LLC indicating that as of March 20, 2025, it held 52,489 shares of the then outstanding 3,638,344 shares, and therefore crossed...

Leuven, BELGIUM – March 27, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received an amended transparency notification as follows: Oxurion received a transparency notification on March 27, 2025, from Atlas Special Opportunities II, LLC indicating that as of March 17, 2025, it held 134,344 shares of the then outstanding 3,638,344 shares, and therefore...

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment [1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM – 24 March, 2025 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May 2,...

Louvain, BELGIUM – March 18, 2025 – 6:30 PM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the signing of a letter of intent (LOI) for the planned acquisition of a majority stake in a Contract Research Organization (CRO) specialized in clinical data management and biometric analysis. This planned acquisition aligns with Oxurion's strategy to expand its expertise by developing an integrated offering for pharmaceutical and biotech...

Leuven, BELGIUM – March 18, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received transparency notifications as follows: Oxurion received a transparency notification on March 18, 2025, from Atlas Special Opportunities, LLC indicating that as of February 17, 2025, it held 485,109 shares of the then outstanding 3,638,344 shares, and therefore crossed...